HealthQuill Drugs
Daraxonrasib belongs to a new class of therapies known as RAS(ON) multi-selective inhibitors.
Drugs Health

New pancreatic cancer vaccine shows promise in preventing recurrence in trial-1

HQ Team August 12, 2025: A new study published in the journal Nature Medicine has shown promising results for an experimental vaccine, ELI-002.

Read More
Novartis AG, a global Switzerland-based pharmaceutical company, has agreed to pay Monte Rosa Therapeutics Inc., $150 million upfront to develop, manufacture and commercialise drug candidates, mainly in immunology.
Drugs Research

Novartis’s Ianalumab has positive Phase III results for Sjögren’s Syndrome

HQ Team August. 11, 2025: Novartis AG announced positive Phase III trial results for its experimental autoimmune drug, Ianalumab (VAY736), in treating Sjögren’s.

Read More
Jazz Pharmaceuticals Plc’s treatment for a rare and aggressive brain tumour that affects children and adults got approval from the US regulator.
Drugs Health Pharma

Jazz Pharma’s oral drug for a type of brain tumour gets US approval 

Jazz Pharmaceuticals Plc’s treatment for a rare and aggressive brain tumour that affects children and adults got approval from the US regulator.

Read More
The Gates Foundation will support more than 40 innovations in five chronically underfunded areas in women’s health by spending $2.5 billion over the next five years.
Drugs Health Pharma

Gates Foundation to spend $2.5 billion on women’s health innovations

The Gates Foundation will support more than 40 innovations in five chronically underfunded areas in women’s health by spending $2.5 billion over the.

Read More
The US Food and Drug Administration has approved Apellis Pharmaceuticals, Inc.’s medicine for treating two rare and serious kidney diseases.
Drugs Health Pharma

FDA approves Apellis’ therapy to treat two serious, rare kidney diseases

HQ Team July 30, 2025: The US Food and Drug Administration has approved Apellis Pharmaceuticals, Inc.’s medicine for treating two rare and serious.

Read More
The US Food and Drug Administration cleared PTC Therapeutics’ sepiapterin for treating children and adults with a rare genetic condition where the body cannot break down a part of protein called phenylalanine, which comes from foods like meat, eggs, and milk.
Drugs Health Pharma

US regulator clears PTC’s medicine to treat a rare genetic metabolic disease 

HQ Team July 29, 2025: The US Food and Drug Administration cleared PTC Therapeutics’ sepiapterin for treating children and adults with a rare.

Read More
Britain’s GSK Plc will pay Jiangsu Hengrui Pharmaceuticals $500 million upfront to acquire global licensing rights for the Chinese company’s 12 potential medicines.
Drugs Health Pharma

GSK inks $500m deal with Jiangsu Hengrui for 12 potential medicines

HQ Team July 28, 2025: Britain’s GSK Plc will pay Jiangsu Hengrui Pharmaceuticals $500 million upfront to acquire global licensing rights for the.

Read More
At least 24 children under the age of five died of malnutrition this month in the conflict-ridden Gaza Strip, taking the overall total of such deaths to 63 in July, according to the World Health Organization.
Drugs Health Medical

Malnutrition claims lives of 24 children in Gaza Strip, hospital cases surge

HQ Team July 28, 2025: At least 24 children under the age of five died of malnutrition this month in the conflict-ridden Gaza.

Read More
Vicebio will receive potential milestone payments of up to $450 million based on development and regulatory achievements.
Drugs Health Pharma

Sanofi to acquire UK’s Vicebio for $1.6b, to pocket vaccine candidates

 HQ Team July 22, 2025: Sanofi SA will acquire UK-based Vicebio Ltd. for $1.6 billion to gain access to vaccine candidates for respiratory.

Read More
Swedish-British AstraZeneca Plc. plans to build a new facility in the US to manufacture drug components for weight management and metabolism, and invest $50 billion in the country over five years.
Drugs Health Pharma

AstraZeneca to invest $50 billion in US, to build new drug facility

HQ Team July 22, 2025: Swedish-British AstraZeneca Plc. plans to build a new facility in the US to manufacture drug components for weight.

Read More